-
公开(公告)号：EP1986633A2
公开(公告)日：2008-11-05
申请号：EP07705368.4
申请日：2007-02-09
发明人： WYNNE, Graham Michael , WREN, Stephen Paul , JOHNSON, Peter David , PRICE, Paul Damien , DE MOOR, Olivier , NUGENT, Gary , STORER, Richard , PYE, Richard Joseph , DORGAN, Colin Richard
IPC分类号： A61K31/343 , A61K31/404 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/4525 , A61K31/454 , A61K31/4709
CPC分类号： C07F9/4003 , A61K31/343 , A61K31/404 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/4525 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377
摘要： There are disclosed compound of Formula (1): A1, A2, A3 and A4 which may be the same or different, represent N or CR1, X is a divalent group selected from O, S(O)n, C=W, NR4, NC(=O)R5 and CR6R7, W is O, S, NR20, Y is N or CR8, one of R4, R5, R6, R8, R9 and NR20 represents - L -R3, in which L is a single bond or a linker group, additionally, R1, R3 - R9, which may be the same or different, independently represent hydrogen or a substituent and R20 represents hydrogen, hydroxyl, alkyl optionally substituted by aryl, alkoxy optionally substituted by aryl, aryl, CN, optionally substituted alkoxy, optionally substituted aryloxy, optionally substitute alkanoyl, optionally substituted aroyl, NO2, NR30R31, in which R30 and R31, which may be the same or different, represent hydrogen, optionally substituted alkyl or optionally substituted aryl; additionally, one of R30 and R31 may represent optionally substituted alkanoyl or optionally substituted aroyl, n represents an integer from 0 to 2, in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when X is CR6R7, R6 and R7, together with the carbon atom to which they are attached may form a ring C, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
-
公开(公告)号：EP2170325A2
公开(公告)日：2010-04-07
申请号：EP08788621.4
申请日：2008-08-01
发明人： WYNNE, Graham Michael , WREN, Stephen Paul , JOHNSON, Peter David , PRICE, Paul Damien , DE MOOR, Olivier , NUGENT, Gary , STORER, Richard , PYE, Richard Joseph , DORGAN, Colin Richard
IPC分类号： A61K31/4192 , A61K31/416 , A61K45/00 , A61P21/00
CPC分类号： A61K45/06 , A61K31/416 , A61K31/4192 , A61K2300/00
摘要： Combinations comprising (or consisting essentially of) one or more compounds of the formula (I) or (II) with one or more ancillary compounds, to processes for preparing the combinations, and to various therapeutic uses of the combinations. Also provided are pharmaceutical compositions containing the combinations as well as a method of treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia using the combinations.
摘要翻译： 包含一种或多种式（I）或（II）化合物与一种或多种辅助化合物（或基本上由其组成）的组合，用于制备组合的方法以及组合的各种治疗用途。 还提供了含有所述组合的药物组合物以及使用所述组合治疗杜氏肌营养不良，贝克肌营养不良或恶病质的方法。
-
公开(公告)号：EP1986643A1
公开(公告)日：2008-11-05
申请号：EP07705369.2
申请日：2007-02-09
发明人： WYNNE, Graham Michael , WREN, Stephen Paul , JOHNSON, Peter David , PRICE, Paul Damien , DE MOOR, Olivier , NUGENT, Gary , DORGAN, Colin Richard , STORER, Richard , PYE, Richard
IPC分类号： A61K31/416 , A61K31/4192 , A61P21/00
CPC分类号： A61K31/416 , A61K31/4192
摘要： There are disclosed compound of Formula (I) or (II) wherein A1, A2, A3, A4and A5, which may be the same or different, represent N or CR1, R9 represents - L -R3, in which L is a single bond or a linker group and R3 represents hydrogen or a substituent and in addition, when an adjacent pair of A1 - A4 each represent CR1, then the adjacent carbon atoms, together with their substituents may form a ring B, when A5 represents CR1, then A5 and N - R9, together with their substituents may form a ring C, or a harmaceutically acceptable salt thereof, in the manufacture of a medicament for the therapeutic and/or prophylactic treatment of Duchenne muscular dystrophy, Becker muscular dystrophy or cachexia.
摘要翻译： 公开了式（I）或（II）的化合物，其中A 1，A 2，A 3，A 4和A 5可以相同或不同，表示N或CR 1，R 9表示-LR 3，其中L是单键 或连接基团，并且R 3表示氢或取代基，另外，当相邻的一对A 1 -A 4各自表示CR 1时，则当A5表示CR 1时，相邻的碳原子连同它们的取代基可以形成环B，则A5 和N-R9与它们的取代基一起可以形成环C或其药学上可接受的盐在制备用于治疗和/或预防性治疗杜氏肌营养不良，贝克肌营养不良或恶病质的药物中的用途。
-
4.发明授权
公开(公告)号：EP2170396B1
公开(公告)日：2016-12-21
申请号：EP08788620.6
申请日：2008-08-01
发明人： WYNNE, Graham Michael , WREN, Stephen Paul , JOHNSON, Peter David , PRICE, Paul Damien , DE MOOR, Olivier , NUGENT, Gary , STORER, Richard , PYE, Richard Joseph , DORGAN, Colin Richard , TINSLEY, Jonathon Mark
IPC分类号： A61K31/423 , A61K31/573
CPC分类号： A61K31/573 , A61K31/423 , A61K45/06 , C07D263/58 , A61K2300/00
-
公开(公告)号：EP1986633B1
公开(公告)日：2014-07-30
申请号：EP07705368.4
申请日：2007-02-09
发明人： WYNNE, Graham Michael , WREN, Stephen Paul , JOHNSON, Peter David , PRICE, Paul Damien , DE MOOR, Olivier , NUGENT, Gary , STORER, Richard , PYE, Richard Joseph , DORGAN, Colin Richard
IPC分类号： A61K31/343 , A61K31/404 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/4525 , A61K31/454 , A61K31/4709 , A61P21/00
CPC分类号： C07F9/4003 , A61K31/343 , A61K31/404 , A61K31/4184 , A61K31/4192 , A61K31/4196 , A61K31/423 , A61K31/4245 , A61K31/426 , A61K31/4355 , A61K31/4365 , A61K31/437 , A61K31/4439 , A61K31/4525 , A61K31/454 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/517 , A61K31/5377
-
公开(公告)号：EP3095783A1
公开(公告)日：2016-11-23
申请号：EP16155561.0
申请日：2009-12-01
发明人： WILSON, Francis Xavier , JOHNSON, Peter David , VICKERS, Richard , STORER, Richard , WYNNE, Graham Michael , ROACH, Alan Geoffrey , DE MOOR, Olivier , DORGAN, Colin Richard , DAVIS, Paul James
IPC分类号： C07D235/18 , C07D401/14 , A61K31/4184 , A61P31/04
CPC分类号： A61K31/444 , A61K31/4439 , C07D235/18 , C07D401/14 , Y02A50/473
摘要： Disclosed are pharmaceutical compositions comprising the compound 2,2'-di(pyridin-4-yl)-1H,1'H-5,5'-bibenzo[d]imidazole, or a pharmaceutically acceptable N-oxide, salt, hydrate or solvate thereof, and a pharmaceutically acceptable excipient. The compositions find application in methods of treating infection with Clostridium difficile and in methods of treating Clostridium difficile -associated disease (CDAD).
摘要翻译： 公开了包含化合物2,2'-二（吡啶-4-基）-1H，1'H-5,5'-联苯并[d]咪唑或其药学上可接受的N-氧化物，盐，水合物或 其溶剂化物和药学上可接受的赋形剂。 该组合物可用于治疗艰难梭菌感染的方法以及治疗艰难梭菌相关疾病（CDAD）的方法中。
-
7.发明公开
公开(公告)号：EP2681190A1
公开(公告)日：2014-01-08
申请号：EP12718709.4
申请日：2012-03-01
发明人： STORER, Richard , TINSLEY, Jonathon Mark , WILSON, Francis Xavier , HORNE, Graeme , WREN, Stephen Paul , DORGAN, Colin Richard , VAN WELL, Renate Maria , FOWLER, Lindsay , CZEMERYS, Louise
IPC分类号： C07D207/12 , C07D207/16 , A61K31/40 , A61K31/401 , A61P9/10 , A61P11/06 , A61P25/28 , A61P37/00
CPC分类号： C07D207/12 , C07D207/16
摘要： Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt, derivative, solvate, isomer, tautomer, N-oxide, ester, prodrug, isotope or protected form thereof, which are of use as OGA inhibitors, for example in the treatment of various conditions and diseases, including neurodegenerative disorders.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.013 秒)
